# Prophylaxis of Hematologic Complications With Naderin in First-Line Breast Cancer Chemotherapy

> **NCT07671547** · PHASE2,PHASE3 · COMPLETED · sponsor: **MIPO Clinic** · enrollment: 79 (actual)

## Conditions studied

- Breast Cancer
- Hematologic Disorder
- Leukopenia
- Chemotherapy-Induced Myelosuppression

## Interventions

- **DRUG:** Naderin
- **DRUG:** AC Chemotherapy

## Key facts

- **NCT ID:** NCT07671547
- **Lead sponsor:** MIPO Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-01
- **Primary completion:** 2015-12-31
- **Final completion:** 2016-12-01
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2026-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07671547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07671547, "Prophylaxis of Hematologic Complications With Naderin in First-Line Breast Cancer Chemotherapy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07671547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*